Pharmacology of orismilast, a potent and selective PDE4 inhibitor
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.18818
Abstract: There remains an unmet need for oral medications that are safe and efficacious for long‐term management of chronic inflammatory skin diseases (CISD). Inhibition of phosphodiesterase 4 (PDE4) can modulate a broad range of pro‐inflammatory cytokines… read more here.
Keywords: pharmacology; pharmacology orismilast; orismilast potent; pde4 ... See more keywords